RxDoctor Payments Data

Marc Lewin, MD

Family Medicine · Charlotte, NCNPI 1023037447

Payments from drug & device makers

$1,493in general payments, 2019–2025

Across 14 payments — averaging $106.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$384
  • Abbott$376
  • AstraZeneca$250
  • Johnson & Johnson$129
  • Sanofi$110
  • Tris Pharma Inc$107
  • plus $137 from 2 others

What the payments were for

  • Speaking & faculty fees$1107%
  • Food & beverage$1,38393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,493 in reported general payments places this provider in the 75th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$81,150
Medicare patients
249
Services billed
879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$88,123
EliquisApixaban29$46,408
RybelsusSemaglutide22$43,022
OzempicSemaglutide28$37,253
JanuviaSitagliptin Phosphate13$20,692
Breo ElliptaFluticasone/Vilanterol34$20,656
FarxigaDapagliflozin Propanediol15$14,690
LivaloPitavastatin Calcium11$3,995
Atorvastatin Calcium508$3,168
SymbicortBudesonide/Formoterol Fumarate12$3,155
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$2,634
Levothyroxine Sodium269$2,179
Bupropion XlBupropion Hcl54$1,788
Wixela InhubFluticasone Propion/Salmeterol14$1,776
SynthroidLevothyroxine Sodium12$1,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$384$20,65634 claims
AstraZenecaFarxiga, Symbicort$250$17,84427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →